Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing α-gal epitopes

Vaccine

Volumn 28, Issue 7, 2010, Pages 1758-1765

  Abdel Motal, Ussama M ^a   Wang, Shixia ^a   Awad, Amany ^b   Lu, Shan ^a   Wigglesworth, Kim ^a   Galili, Uri ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alpha gal epitopes; HIV; Immunogenicity; Vaccine

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; GAG PROTEIN; GALACTOSE; GAMMA INTERFERON; GLYCOPROTEIN GP 120;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GALACTOSYLTRANSFERASES; GLYCOSYLATION; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; MALE; MICE; MICE, KNOCKOUT; RECOMBINANT FUSION PROTEINS; TRISACCHARIDES;

EID: 75249107663     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.015     Document Type: Article

References (40)

1. Bucy R.P., and Kilby J.M. Perspectives on inducing efficient immune control of HIV-1 replication-a new goal for HIV therapeutics?. AIDS 15 Suppl. 2 (2001) S36-42
2. Berzofsky J.A., Ahlers J.D., Janik J., Morris J., Oh S., Terabe M., et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114 4 (2004) 450-462
3. Buge S.L., Ma H.L., Amara R.R., Wyatt L.S., Earl P.L., Villinger F., et al. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res Hum Retroviruses 19 10 (2003) 891-900
4. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5 3 (2004) 233-236
5. Goulder P.J., and Watkins D.I. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4 8 (2004) 630-640
6. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 6916 (2002) 678-682
7. Letvin N.L. Progress toward an HIV vaccine. Annu Rev Med 56 (2005) 213-223
8. Pantaleo G., and Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10 8 (2004) 806-810
9. Pincus S.H., Wehrly K., Tschachler E., Hayes S.F., Buller R.S., and Reitz M. Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin. J Exp Med 172 3 (1990) 745-757
10. Thomson M.M., Perez-Alvarez L., and Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2 8 (2002) 461-471
11. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature 422 6929 (2003) 307-312
12. Abdel-Motal U., Wang S., Lu S., Wigglesworth K., and Galili U. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galα1-3Galβ1-4GlcNAc-R epitopes. J Virol 80 14 (2006) 6943-6951
13. Galili U., Rachmilewitz E.A., Peleg A., and Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 160 5 (1984) 1519-1531
14. Galili U. Evolution and pathophysiology of the human natural anti-α-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol 15 2-3 (1993) 155-171
15. Galili U., Macher B.A., Buehler J., and Shohet S.B. Human natural anti-α-galactosyl IgG. II. The specific recognition of α (1-3)-linked galactose residues. J Exp Med 162 2 (1985) 573-582
16. Galili U., Clark M.R., Shohet S.B., Buehler J., and Macher B.A. Evolutionary relationship between the natural anti-Gal antibody and the Gal α 1-3Gal epitope in primates. Proc Natl Acad Sci USA 84 5 (1987) 1369-1373
17. Galili U., Shohet S.B., Kobrin E., Stults C.L., and Macher B.A. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 263 33 (1988) 17755-17762
18. Larsen R.D., Rivera-Marrero C.A., Ernst L.K., Cummings R.D., and Lowe J.B. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:β-d-Gal(1,4)-d-GlcNAc α(1,3)-galactosyltransferase cDNA. J Biol Chem 265 12 (1990) 7055-7061
19. Galili U., and LaTemple D.C. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 18 6 (1997) 281-285
20. LaTemple D.C., Abrams J.T., Zhang S.Y., and Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for α1,3galactosyltransferase. Cancer Res 59 14 (1999) 3417-3423
21. Manches O., Plumas J., Lui G., Chaperot L., Molens J.P., Sotto J.J., et al. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells. Haematologica 90 5 (2005) 625-634
22. Clynes R., Takechi Y., Moroi Y., Houghton A., and Ravetch J.V. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95 2 (1998) 652-656
23. Abdel-Motal U.M., Guay H.M., Wigglesworth K., Welsh R.M., and Galili U. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. J Virol 81 17 (2007) 9131-9141
24. Maness N.J., Yant L.J., Chung C., Loffredo J.T., Friedrich T.C., Piaskowski S.M., et al. Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-B*17-positive Simian immunodeficiency virus-infected rhesus macaques. J Virol 82 11 (2008) 5245-5254
25. Chen Z.C., Tanemura M., and Galili U. Synthesis of α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) on human tumor cells by recombinant α1,3galactosyltransferase produced in Pichia pastoris. Glycobiology 11 7 (2001) 577-586
26. Galili U., LaTemple D.C., and Radic M.Z. A sensitive assay for measuring α-Gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation 65 8 (1998) 1129-1132
27. Thall A.D., Maly P., and Lowe J.B. Oocyte Gal α 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 270 37 (1995) 21437-21440
28. Henion T.R., Gerhard W., Anaraki F., and Galili U. Synthesis of α-gal epitopes on influenza virus vaccines, by recombinant α 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody. Vaccine 15 11 (1997) 1174-1182
29. LaTemple D.C., and Galili U. Adult and neonatal anti-Gal response in knock-out mice for α1,3galactosyltransferase. Xenotransplantation 5 3 (1998) 191-196
30. Wang S., Arthos J., Lawrence J.M., Van Ryk D., Mboudjeka I., Shen S., et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 79 12 (2005) 7933-7937
31. Lu S., Santoro J.C., Fuller D.H., Haynes J.R., and Robinson H.L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 209 1 (1995) 147-154
32. Wang S., Farfan-Arribas D.J., Shen S., Chou T.H., Hirsch A., He F., et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 24 21 (2006) 4531-4540
33. Derby N.R., Kraft Z., Kan E., Crooks E.T., Barnett S.W., Srivastava I.K., et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 80 17 (2006) 8745-8762
34. Abdel-Motal U.M., Gillis J., Manson K., Wyand M., Montefiori D., Stefano-Cole K., et al. Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques. Virology 333 2 (2005) 226-238
35. Qiu J.T., Song R., Dettenhofer M., Tian C., August T., Felber B.K., et al. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J Virol 73 11 (1999) 9145-9152
36. Bottrel R.L., Dutra W.O., Martins F.A., Gontijo B., Carvalho E., Barral-Netto M., et al. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun 69 5 (2001) 3232-3239
37. Unkeless J.C. Function and heterogeneity of human Fc receptors for immunoglobulin G. J Clin Invest 83 2 (1989) 355-361
38. Fanger N.A., Wardwell K., Shen L., Tedder T.F., and Guyre P.M. Type I (CD64) and type II (CD32) Fc γ receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 157 2 (1996) 541-548
39. Schmitt D.A., Hanau D., Bieber T., Dezutter-Dambuyant C., Schmitt D., Fabre M., et al. Human epidermal Langerhans cells express only the 40-kilodalton Fc γ receptor (FcRII). J Immunol 144 11 (1990) 4284-4290
40. Abdel-Motal U.M., Wigglesworth K., and Galili U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine 27 23 (2009) 3072-3082